Oppenheimer initiated coverage of ARS Pharmaceuticals (SPRY) with an Outperform rating and $40 price target As the first and only approved needle-free epinephrine product, neffy has the potential ...

In a report released today, Annabel Samimy from Stifel Nicolaus maintained a Buy rating on Phathom Pharmaceuticals (PHAT – Research Report), with a price target of $28.00. The company’s shares ...

Infinity Pharmaceuticals Inc. 0.00% $90.76 ...

IPC Indice de Precios Y Cotizaciones 52,817.75 142.96 0.27% ...

The 21st century pharmaceutical and biotech sector has come a long way from its roots in 19th century pharmacy. pharmaphorum looks at its evolution over the centuries. The roots of the ...

Rocket Pharmaceuticals (RCKT) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising ...

In today’s fast-paced world, threats can evolve quickly and without warning. As the pharmaceutical industry has operations and supply chains spanning the globe, companies are vulnerable to ...

2025 The U.S. Food and Drug Administration has approved Supernus Pharmaceuticals' drug-device combination to treat movement-related symptoms of Parkinson's disease, the drugmaker said on Tuesday.

After hours: February 11 at 4:25:59 PM EST Loading Chart for XENE ...

Biopharmaceutical company developing drugs for neurological disorders.

In the first part of his video interview with Pharma Commerce Editor Nicholas Saraceno, Alex Guillen, global pharma and life sciences director at Tive, outlines the technological obstacles that lie ...